Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1247MR)

This product GTTS-WQ1247MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1247MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14919MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ5377MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3142MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ11341MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ5886MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ9921MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ6435MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ987MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW